Recent News

Opioid Liability for Injury and Death

The opioid industry is facing unprecedented backlash from private citizens and government officials as more individuals fall victim to addiction, injury and even death related to opioid use. Here, the product liability attorneys at The Law Offices of Peter G. Angelos discuss who may be held liable for injuries or death related to opioid use….

Read More...

Jury Awards $27.8 Million in Damages to Patient Injured by Xarelto®

On December 5, 2017, a Philadelphia jury ordered Bayer AG and Johnson & Johnson to pay over $27 million in damages to a patient injured by the companies’ most lucrative medication, Xarelto®. In a verdict that marks the first patient victory in the ongoing Xarelto® litigation, a Philadelphia jury ordered Bayer AG and Johnson &…

Read More...

FDA: Clinical Trials Show Increased Risk of Amputation with Invokana

Recent safety communications published by the US Food and Drug Administration indicate that type 2 diabetes drug, Invokana (canagliflozin), can cause increased risk for foot and leg amputations. This announcement was made after data from two clinical studies showed that such amputations were necessary in nearly twice as many patients taking Invokana as compared to…

Read More...

What Patients Need to Know About Actos

The pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the dangers of Actos—a common Type 2 Diabetes medication. Actos, a common Type 2 Diabetes medication manufactured by Takeda Pharmaceuticals, has remained at the center of thousands of patient injury lawsuits over the past several years. These lawsuits claim that Takeda Pharmaceuticals withheld…

Read More...

Xarelto®: A Year in Review

In November, 2015, the U.S. District Court for the Eastern District of Louisiana announced that the first of the Xarelto® bellwether trials, stemming from the Xarelto® multidistrict litigation, would begin in February, 2017. Since that announcement, there have been many updates in the ongoing legal battle against Xarelto® manufacturer Bayer AG and distributer Janssen Pharmaceuticals….

Read More...

PPI Lawsuits: What’s Next?

The pharmaceutical liability attorneys at The Law Offices of Peter Angelos provide information regarding the risks related to proton pump inhibitors and the lawsuits filed by PPI consumers. Proton pump inhibitors (PPI) are used to treat a number of common abdominal conditions such as gastroesophageal reflux disease, stomach and duodenal ulcers, heartburn and erosive esophagitis….

Read More...

Families Claim that Manufacturer Should Have Warned of Zofran Risks

The FDA approved Zofran, an antiemetic medication manufactured by GlaxoSmithKline (GSK) to prevent nausea and vomiting caused by cancer chemo therapy, radiation therapy, and surgery. Although Zofran was approved for distribution only for chemotherapy and radiation patients, GSK promoted the drug as an effective means to fight the same symptoms in pregnant women. Over the…

Read More...

New Risk Associated with PPI Drugs

Proton pump inhibitors (PPIs) are a class of medication used to treat a number of common abdominal conditions such as gastroesophageal reflux disease, stomach and duodenal ulcers, heartburn and erosive esophagitis. Consumer brand PPIs include Nexium, Prevacid and Prilosec. Yet, a recent study, which includes data from nearly 200,000 patients treated through the Department of…

Read More...

Blood Thinner Safety: What to Know When Taking Xarelto

Blood clots have the ability to prevent blood flow to patients’ organs such as the heart, lungs, and kidneys, potentially causing stroke and other life-threatening health conditions. There are many different medications on the market today that aim to reduce the risk of dangerous health conditions such as deep vein thrombosis, blood clot and stroke….

Read More...

Studies Suggest Common Acid Reflux Medication Could Cause Severe Side Effects

Proton pump inhibitors (PPIs) are a class of medication used to treat a number of common abdominal conditions such as gastroesophageal reflux disease, stomach and duodenal ulcers, heartburn and erosive esophagitis. The medication works by obstructing the proton pump—an integral membrane protein—which then restricts or blocks the release of acid into a patient’s stomach. Common…

Read More...